What question did this study set out to answer?

To investigate how low-dose intestinal irradiation affects the efficacy of PD-1 blockade in metastatic non-small cell lung cancer (mNSCLC).

March 21, 2026Open Access

View Full Paper

Low-dose intestinal irradiation enhances the efficacy and prognosis of PD-1 blockade in metastatic non-small cell lung cancer

BHBaiyang HuangShandong Tumor Hospital JZJie ZhaoTianjin Hospital JZJiye ZhuChinese Academy of Medical Sciences & Peking Union Medical College

Key Points

To investigate how low-dose intestinal irradiation affects the efficacy of PD-1 blockade in metastatic non-small cell lung cancer (mNSCLC).
Examined the influence of intestinal irradiation on PD-1 blockade efficacy.
Maintained doses of 1-3 Gy for irradiation.
Assessed changes in gut microbiota and immune responses.
Low-dose intestinal irradiation enhances the response to PD-1 blockade.
Improved patient prognosis observed with intestinal irradiation combined with PD-1 therapy.
Changes in gut microbiota linked to enhanced immune responses.

Abstract

ILDR influences the efficacy of PD-1 blockade in patients with mNSCLC, particularly when SIMRD is maintained within the 1-3 Gy range, likely through modulation of the gut microbiota-metabolite-immune axis.

AIに質問

Bookmark

View Full Paper

AIに質問

Bookmark

View Full Paper

Low-dose intestinal irradiation enhances the efficacy and prognosis of PD-1 blockade in metastatic non-small cell lung cancer

Key Points

Abstract

Cite This Study

Also Consider

Also Consider